PharmNovo
Edit

PharmNovo

https://www.pharmnovo.com/
Last activity: 21.03.2024
Categories: BioTechDevelopmentDrugLifeMedTechProductionScience
PharmNovo aims to provide safe and effective medicines for chronic pain therapy, based on novel Delta Opioid Receptor Agonists (DORAs). This is a very different target compared with conventional opioid drugs which are responsible for an epidemic of addiction and toxicity. We address the high unmet medical need for safe and effective treatments for chronic pain, which affects up to 30% of the adult population in the USA and Europe. Currently available treatments are not very effective and associated with severe side-effects. PharmNovo’s candidate compound, PN6047, is a completely new, biased signalling DORA that effectively reduces chronic pain in animal models and shows no tolerance or side-effects such as the respiratory depression and drug abuse associated with conventional opioids. PharmNovo AB is now seeking investors to fund large-scale production of the compound, GLP regulatory Toxicology, build up of the company and the preparation for Phase l clinical studies of PN6047 for chronic pain treatment.
Mentions
13
Employees: 11-50
Total raised: $6.89M
Founded date: 2008

Investors 1

DateNameWebsite
-Almi Inves...almi.se

Funding Rounds 1

DateSeriesAmountInvestors
03.06.2022-$6.89M-

Mentions in press and media 13

DateTitleDescriptionSource
21.03.2024PharmNovo announces positive Phase I results for neuropathic...PharmNovo announces positive Phase I results for neuropathic pain management drug PN6047 Thu, Mar 21...news.cisio...
01.12.2023NIDA funds studies on PN6047 from PharmNovo for potential op...NIDA funds studies on PN6047 from PharmNovo for potential opioid withdrawal treatment Fri, Dec 01, 2...news.cisio...
18.10.2023PharmNovo signs agreement with Worldwide Clinical Trials for...PharmNovo signs agreement with Worldwide Clinical Trials for phase IIa study of PN6047 in neuropathi...news.cisio...
02.10.2023Sciety’s portfolio company PharmNovo reports positive headli...PRESS RELEASE. Sciety’s portfolio company PharmNovo, a Swedish pharmaceutical company based in Lund,...sciety.com...
02.10.2023PharmNovo successfully completes phase I study with lead can...PharmNovo successfully completes phase I study with lead candidate PN6047 Mon, Oct 02, 2023 08:00 CE...news.cisio...
28.09.2023PharmNovo reports promising preclinical results on abuse pot...PharmNovo reports promising preclinical results on abuse potential and withdrawal symptom relief Thu...news.cisio...
12.09.2023PharmNovo appoints Alexander Dahlquist as new CFOPharmNovo appoints Alexander Dahlquist as new CFO Tue, Sep 12, 2023 07:30 CET Report this content Th...news.cisio...
25.05.2023PharmNovo strengthens the team with Project Leader/COOPharmNovo strengthens the team with Project Leader/COO Thu, May 25, 2023 07:45 CET Report this conte...news.cisio...
05.09.2022PharmNovo appoints CFO and Clinical Lead to strengthen the o...PharmNovo appoints CFO and Clinical Lead to strengthen the organisation Mon, Sep 05, 2022 09:40 CET ...news.cisio...
19.08.2022PharmNovo starts clinical phase I studies of a drug candidat...PharmNovo starts clinical phase I studies of a drug candidate for neuropathic pain Fri, Aug 19, 2022...news.cisio...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In